Avian influenza continues to circulate and remains a global health threat not least because of the associated high mortality. In this study antibody persistence, booster vaccine response and cross-clade immune response between two influenza A(H5N1) vaccines were compared. Participants aged over 18-years who had previously been immunized with a clade 1, A/Vietnam vaccine were re-immunized at 6-months with 7.5 μg of the homologous strain or at 22-months with a clade 2, alum-adjuvanted, A/Indonesia vaccine. Blood sampled at 6, 15 and 22-months after the primary course was used to assess antibody persistence. Antibody concentrations 6-months after primary immunisation with either A/Vietnam vaccine 30 μg alum-adjuvanted vaccine or 7.5 μg dose vaccine were lower than 21-days after the primary course and waned further with time. Re-immunization with the clade 2, 30 μg alum-adjuvanted vaccine confirmed cross-clade reactogenicity. Antibody cross-reactivity between A(H5N1) clades suggests that in principle a prime-boost vaccination strategy may provide both early protection at the start of a pandemic and improved antibody responses to specific vaccination once available. TRIAL REGISTRATION: ClinicalTrials.gov NCT00415129.

Original publication

DOI

10.1371/journal.pone.0165384

Type

Journal

PLoS One

Publication Date

2016

Volume

11

Keywords

Adjuvants, Immunologic, Adolescent, Adult, Animals, Antibodies, Viral, Antibody Formation, Birds, Humans, Immunization, Secondary, Indonesia, Influenza A Virus, H5N1 Subtype, Influenza Vaccines, Influenza in Birds, Influenza, Human, Male, Middle Aged, Neutralization Tests, Vaccination, Vietnam, Virion, Young Adult